Company type | Societas Europaea |
---|---|
Euronext Paris: VLA | |
ISIN | FR0004056851 |
Industry | Biotechnology |
Predecessor | Merger of Intercell and Vivalis SA |
Founded | 2013 |
Headquarters | , |
Key people | Thomas Lingelbach (CEO), Frédéric Grimaud (Chairman of the supervisory board) |
Products | Development of vaccines |
Website | www |
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.[1][2][3]